239 related articles for article (PubMed ID: 30657911)
1. Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes.
Kushchayeva YS; Kushchayev SV; Startzell M; Cochran E; Auh S; Dai Y; Lightbourne M; Skarulis M; Brown RJ
J Clin Endocrinol Metab; 2019 Jun; 104(6):2216-2228. PubMed ID: 30657911
[TBL] [Abstract][Full Text] [Related]
2. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
3. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of adolescent cases with Type A insulin resistance syndrome caused by heterozygous mutations in the β-subunit of the insulin receptor (INSR) gene.
Takasawa K; Tsuji-Hosokawa A; Takishima S; Wada Y; Nagasaki K; Dateki S; Numakura C; Hijikata A; Shirai T; Kashimada K; Morio T
J Diabetes; 2019 Jan; 11(1):46-54. PubMed ID: 29877041
[TBL] [Abstract][Full Text] [Related]
5. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
[TBL] [Abstract][Full Text] [Related]
6. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
Vatier C; Fetita S; Boudou P; Tchankou C; Deville L; Riveline J; Young J; Mathivon L; Travert F; Morin D; Cahen J; Lascols O; Andreelli F; Reznik Y; Mongeois E; Madelaine I; Vantyghem M; Gautier J; Vigouroux C
Diabetes Obes Metab; 2016 Jul; 18(7):693-7. PubMed ID: 26584826
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Effects of Metreleptin in Rabson-Mendenhall Syndrome on Glycemia, Growth, and Kidney Function.
Okawa MC; Cochran E; Lightbourne M; Brown RJ
J Clin Endocrinol Metab; 2022 Feb; 107(3):e1032-e1046. PubMed ID: 34718628
[TBL] [Abstract][Full Text] [Related]
8. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
[TBL] [Abstract][Full Text] [Related]
9. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
[TBL] [Abstract][Full Text] [Related]
10. Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides.
Joseph J; Shamburek RD; Cochran EK; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1676-80. PubMed ID: 24926953
[TBL] [Abstract][Full Text] [Related]
11. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
Lambadiari V; Kountouri A; Maratou E; Liatis S; Dimitriadis GD; Karpe F
Front Endocrinol (Lausanne); 2021; 12():684182. PubMed ID: 34168618
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
[TBL] [Abstract][Full Text] [Related]
15. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
[TBL] [Abstract][Full Text] [Related]
16. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy.
Grover A; Quaye E; Brychta RJ; Christensen J; Startzell MS; Meehan CA; Valencia A; Marshall B; Chen KY; Brown RJ
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4163-e4178. PubMed ID: 33890058
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ
Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105
[TBL] [Abstract][Full Text] [Related]
18. Leptin Decreases Gluconeogenesis and Gluconeogenic Substrate Availability in Patients With Lipodystrophy.
Quaye E; Chacko S; Startzell M; Brown RJ
J Clin Endocrinol Metab; 2023 Dec; 109(1):e209-e215. PubMed ID: 37515588
[TBL] [Abstract][Full Text] [Related]
19. Thyroid Hormone Effects on Glucose Disposal in Patients With Insulin Receptor Mutations.
Kushchayeva YS; Startzell M; Cochran E; Auh S; Sekizkardes H; Soldin SJ; Kushchayev SV; Dieckmann W; Skarulis M; Abdul Sater Z; Brychta RJ; Cypess AM; Lin TC; Lightbourne M; Millo C; Brown RJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):e158-71. PubMed ID: 31588494
[TBL] [Abstract][Full Text] [Related]
20. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
